vs
辉瑞（PFE）与RYDER SYSTEM INC（R）财务数据对比。点击上方公司名可切换其他公司
辉瑞的季度营收约是RYDER SYSTEM INC的5.6倍（$17.6B vs $3.1B），RYDER SYSTEM INC净利率更高（3.0% vs -9.4%，领先12.4%），RYDER SYSTEM INC同比增速更快（1.0% vs -1.2%），辉瑞自由现金流更多（$4.5B vs $273.0M），过去两年辉瑞的营收复合增速更高（8.6% vs -0.9%）
辉瑞是总部位于美国纽约曼哈顿The Spiral的跨国制药及生物技术企业，由德国企业家查尔斯·辉瑞与查尔斯·F·埃尔哈特于1849年在纽约创立，是北美地区历史最悠久的制药企业之一，在全球医药健康领域拥有较高的行业影响力。
Ryder System Inc.是美国专业运输物流服务商，总部位于佛罗里达州科勒尔盖布尔斯，业务覆盖美国及英国，核心业务包含卡车租赁、车队管理、供应链及运输管理，同时提供车辆维保、二手车销售、专业司机派遣、电商履约与最后一公里配送等多元服务。
PFE vs R — 直观对比
营收规模更大
PFE
是对方的5.6倍
$3.1B
营收增速更快
R
高出2.2%
-1.2%
净利率更高
R
高出12.4%
-9.4%
自由现金流更多
PFE
多$4.2B
$273.0M
两年增速更快
PFE
近两年复合增速
-0.9%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $17.6B | $3.1B |
| 净利润 | $-1.6B | $93.0M |
| 毛利率 | 70.0% | — |
| 营业利润率 | -9.4% | — |
| 净利率 | -9.4% | 3.0% |
| 营收同比 | -1.2% | 1.0% |
| 净利润同比 | -501.7% | -5.1% |
| 每股收益（稀释后） | $-0.29 | $2.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PFER
| Q1 26 | — | $3.1B | ||
| Q4 25 | $17.6B | $3.2B | ||
| Q3 25 | $16.7B | $3.2B | ||
| Q2 25 | $14.7B | $3.2B | ||
| Q1 25 | $13.7B | $3.1B | ||
| Q4 24 | $17.8B | $3.2B | ||
| Q3 24 | $17.7B | $3.2B | ||
| Q2 24 | $13.3B | $3.2B |
净利润PFER
| Q1 26 | — | $93.0M | ||
| Q4 25 | $-1.6B | $132.0M | ||
| Q3 25 | $3.5B | $138.0M | ||
| Q2 25 | $2.9B | $131.0M | ||
| Q1 25 | $3.0B | $98.0M | ||
| Q4 24 | $410.0M | $135.0M | ||
| Q3 24 | $4.5B | $142.0M | ||
| Q2 24 | $41.0M | $127.0M |
毛利率PFER
| Q1 26 | — | — | ||
| Q4 25 | 70.0% | — | ||
| Q3 25 | 74.9% | — | ||
| Q2 25 | 74.2% | — | ||
| Q1 25 | 79.3% | — | ||
| Q4 24 | 66.7% | — | ||
| Q3 24 | 70.3% | — | ||
| Q2 24 | 75.2% | — |
营业利润率PFER
| Q1 26 | — | — | ||
| Q4 25 | -9.4% | 5.6% | ||
| Q3 25 | 20.0% | 6.0% | ||
| Q2 25 | 20.8% | 5.8% | ||
| Q1 25 | 20.3% | 4.3% | ||
| Q4 24 | -0.1% | 5.7% | ||
| Q3 24 | 26.6% | 5.9% | ||
| Q2 24 | -0.8% | 5.6% |
净利率PFER
| Q1 26 | — | 3.0% | ||
| Q4 25 | -9.4% | 4.2% | ||
| Q3 25 | 21.3% | 4.4% | ||
| Q2 25 | 19.9% | 4.1% | ||
| Q1 25 | 21.6% | 3.1% | ||
| Q4 24 | 2.3% | 4.2% | ||
| Q3 24 | 25.2% | 4.5% | ||
| Q2 24 | 0.3% | 4.0% |
每股收益（稀释后）PFER
| Q1 26 | — | $2.34 | ||
| Q4 25 | $-0.29 | $3.22 | ||
| Q3 25 | $0.62 | $3.32 | ||
| Q2 25 | $0.51 | $3.13 | ||
| Q1 25 | $0.52 | $2.27 | ||
| Q4 24 | $0.07 | $3.09 | ||
| Q3 24 | $0.78 | $3.24 | ||
| Q2 24 | $0.01 | $2.84 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $182.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $86.5B | $2.9B |
| 总资产 | $208.2B | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PFER
| Q1 26 | — | $182.0M | ||
| Q4 25 | $1.1B | $198.0M | ||
| Q3 25 | $1.3B | $189.0M | ||
| Q2 25 | $1.6B | $180.0M | ||
| Q1 25 | $1.4B | $151.0M | ||
| Q4 24 | $1.0B | $154.0M | ||
| Q3 24 | $1.1B | $162.0M | ||
| Q2 24 | $1.1B | $164.0M |
总债务PFER
| Q1 26 | — | — | ||
| Q4 25 | — | $6.8B | ||
| Q3 25 | — | $7.3B | ||
| Q2 25 | — | $7.0B | ||
| Q1 25 | — | $6.7B | ||
| Q4 24 | — | $6.7B | ||
| Q3 24 | — | $6.6B | ||
| Q2 24 | — | $6.5B |
股东权益PFER
| Q1 26 | — | $2.9B | ||
| Q4 25 | $86.5B | $3.1B | ||
| Q3 25 | $92.8B | $3.1B | ||
| Q2 25 | $88.7B | $3.1B | ||
| Q1 25 | $90.3B | $3.0B | ||
| Q4 24 | $88.2B | $3.1B | ||
| Q3 24 | $92.3B | $3.1B | ||
| Q2 24 | $87.7B | $3.1B |
总资产PFER
| Q1 26 | — | — | ||
| Q4 25 | $208.2B | $16.4B | ||
| Q3 25 | $208.7B | $16.5B | ||
| Q2 25 | $206.1B | $16.5B | ||
| Q1 25 | $208.0B | $16.4B | ||
| Q4 24 | $213.4B | $16.7B | ||
| Q3 24 | $219.5B | $16.5B | ||
| Q2 24 | $216.2B | $16.4B |
负债/权益比PFER
| Q1 26 | — | — | ||
| Q4 25 | — | 2.24× | ||
| Q3 25 | — | 2.35× | ||
| Q2 25 | — | 2.27× | ||
| Q1 25 | — | 2.21× | ||
| Q4 24 | — | 2.14× | ||
| Q3 24 | — | 2.17× | ||
| Q2 24 | — | 2.09× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.3B | $583.0M |
| 自由现金流经营现金流 - 资本支出 | $4.5B | $273.0M |
| 自由现金流率自由现金流/营收 | 25.6% | 8.7% |
| 资本支出强度资本支出/营收 | 4.8% | 13.7% |
| 现金转化率经营现金流/净利润 | — | 6.27× |
| 过去12个月自由现金流最近4个季度 | $9.1B | $595.0M |
8季度趋势，按日历期对齐
经营现金流PFER
| Q1 26 | — | $583.0M | ||
| Q4 25 | $5.3B | $749.0M | ||
| Q3 25 | $4.6B | $442.0M | ||
| Q2 25 | $-582.0M | $752.0M | ||
| Q1 25 | $2.3B | $651.0M | ||
| Q4 24 | $6.7B | $558.0M | ||
| Q3 24 | $6.7B | $629.0M | ||
| Q2 24 | $-1.8B | $552.0M |
自由现金流PFER
| Q1 26 | — | $273.0M | ||
| Q4 25 | $4.5B | $344.0M | ||
| Q3 25 | $4.0B | $-85.0M | ||
| Q2 25 | $-1.2B | $63.0M | ||
| Q1 25 | $1.8B | $137.0M | ||
| Q4 24 | $5.8B | $-201.0M | ||
| Q3 24 | $6.1B | $30.0M | ||
| Q2 24 | $-2.4B | $-87.0M |
自由现金流率PFER
| Q1 26 | — | 8.7% | ||
| Q4 25 | 25.6% | 10.8% | ||
| Q3 25 | 24.0% | -2.7% | ||
| Q2 25 | -8.2% | 2.0% | ||
| Q1 25 | 12.9% | 4.4% | ||
| Q4 24 | 32.7% | -6.3% | ||
| Q3 24 | 34.3% | 0.9% | ||
| Q2 24 | -18.2% | -2.7% |
资本支出强度PFER
| Q1 26 | — | 13.7% | ||
| Q4 25 | 4.8% | 12.8% | ||
| Q3 25 | 3.6% | 16.6% | ||
| Q2 25 | 4.2% | 21.6% | ||
| Q1 25 | 4.1% | 16.4% | ||
| Q4 24 | 5.2% | 23.8% | ||
| Q3 24 | 3.7% | 18.9% | ||
| Q2 24 | 4.8% | 20.1% |
现金转化率PFER
| Q1 26 | — | 6.27× | ||
| Q4 25 | — | 5.67× | ||
| Q3 25 | 1.30× | 3.20× | ||
| Q2 25 | -0.20× | 5.74× | ||
| Q1 25 | 0.79× | 6.64× | ||
| Q4 24 | 16.39× | 4.13× | ||
| Q3 24 | 1.50× | 4.43× | ||
| Q2 24 | -43.44× | 4.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PFE
| U.S.Commercial Division | $9.0B | 51% |
| Specialty Care | $4.8B | 27% |
| Total Alliance Biopharmaceuticals | $2.6B | 15% |
| Royalty | $480.0M | 3% |
| Pfizer Centre One | $409.0M | 2% |
R
| Fleet Management Solutions | $1.5B | 47% |
| ChoiceLease | $878.0M | 28% |
| Dedicated Transportation Solutions | $553.0M | 18% |
| Commercial rental | $211.0M | 7% |
